ProteoDesign announces new Investment led by Ysios Capital and rebrands as...
ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology....
View ArticleSplice Bio awarded with a “RETOS de Colaboración” grant
Splice Bio awarded with a “RETOS de Colaboración” grant BARCELONA, October 20, 2020 – Splice Bio, a biotech company based on technology developed in the Muir lab at Princeton University, announced...
View ArticleSplice Bio announces research funding by Cystic Fibrosis Foundation to...
Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir...
View ArticleSplice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors
Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed in the Muir Lab at...
View ArticleSpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance...
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline Financing co-led by UCB Ventures and Ysios Capital with...
View ArticleSplice Bio awarded with a “Colaboración Público-Privada” grant
Splice Bio awarded with a “RETOS de Colaboración” grant BARCELONA, January 26, 2023 – SpliceBio, a genetic medicines company on a mission to expand the universe of diseases that can be addressed with...
View ArticleSpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer...
SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program Dr. Favre brings extensive experience in gene therapy,...
View ArticleSpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene...
SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease SpliceBio is eligible to receive upfront, opt-in and milestone payments up to...
View ArticleSpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical...
SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer Dr. Girach is a world-renowned specialist in the field of ophthalmology and gene therapy Appointment further...
View ArticleSpliceBio to Attend and Present at Key Scientific and Investor Conferences in...
SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024 BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company harnessing Protein Splicing to...
View Article